✦ LIBER ✦

BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer

✍ Scribed by M.J. Morris; W.P. Tong; C. Cordon-Cardo; M. Drobnjak; W.K. Kelly; S.F. Slovin; N. Rosen; H.I. Scher

Book ID: 117658656
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 358 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)81293-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Preliminary phase I results of G3139 (bc

Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer

✍ Anthony W Tolcher 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 425 KB

Inhibition of progression to androgen-in

Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model

✍ Hideaki Miyake; Brett P. Monia; Martin E. Gleave 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 184 KB 👁 2 views

We have reported that antisense Bcl-2 oligodeoxynucleotide (ODN) delays progression to androgen independence in the androgen-dependent (AD) mouse Shionogi tumor model. Here, we characterize changes in bcl-xL, another important anti-apoptotic gene, and test the efficacy of adjuvant antisense Bcl-xL O

Up-regulation of Bcl-2 is required for t

Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage

✍ Lin, Yuting; Fukuchi, Junichi; Hiipakka, Richard A; Kokontis, John M; Xiang, Jia 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 421 KB

34 Phase 2 study of neoadjuvant docetaxe

34 Phase 2 study of neoadjuvant docetaxel and androgen suppression (AS) Plus Radiation Therapy (RT) for high risk localized prostate cancer (HRLCaP)

✍ M. McKenzie; K. Chi; A. Neville; S. Ellard; B. Baerg; D. Ruether; E. Winquist; R 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 258 KB

Randomized phase II trial of docetaxel p

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer: Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM, Steinberg SM, Wright JJ, Parnes H, Chen CC, Jones E, Parker CE, Linehan WM, Figg WD, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. J Clin Oncol 2004;22:2532–9

✍ Gurkamal Chatta 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 43 KB